Trial Design Webinars

  1. How Artificial Intelligence Will Revolutionize Safety
    6/19/2019

    Watch this webcast to learn how artificial intelligence, natural language processing, and machine learning are poised to change the way we do pharmacovigilance.

  2. Standardization Drives Transparency And Optimization Of Contract/Budget Processes In Clinical Trial Startup
    6/19/2019

    For years, this laborious step has ranked as the lengthiest of study startup activities, and recent data suggest it remains the primary cause of site activation failure. This webcast will cover How granular metrics empower business intelligence, process optimization and efficient resource allocation and other steps to help avoid bottlenecks and delays.

  3. Refocusing On Risk Mitigation In Starting Clinical Trials
    5/31/2019

    While risk management efforts in drug development have focused mostly on post-marketing drug safety, the clinical trials process has its own mix of potential risks waiting to derail a company's multimillion-dollar development programs. For study startup, a problematic area of clinical trials, these risks include site selection and patient enrollment issues, budget and contracting delays, logistical problems with timely drug shipments, and regulatory hurdles.

  4. How Advanced Therapies Are Changing The Landscape Of Rare Disease
    5/16/2019

    After years of innovative research, advanced therapies are dramatically changing the way patients are treated for a wide variety of diseases – particularly for patients with rare diseases and orphan indications. In this webinar join experts from Medpace’s medical, regulatory and operational team with hands-on experience in rare disease and ATMP development as they explore scientific advancements the regulatory landscape and lessons-learned and best practices for operationalizing rare disease clinical trials including identifying, enrolling and retaining patients, as well as special considerations for ATMPs.

  5. Virtual Study Designs
    5/14/2019

    Virtual study designs are transforming the way biopharmaceutical businesses conduct research. Tactics that decentralize the approach to clinical and observational research are ushering in a new paradigm of efficient data collection and patient centric engagement.

  6. The Big Picture: Impact Of EU Disclosure On Small & Mid-Size Sponsors
    5/6/2019

    With the new EU clinical trial registry portal expected to launch next year, it’s imperative that sponsors – particularly small and mid-size organizations – understand the complexities of EU disclosure. Thomas Wicks, an expert in clinical trial disclosure, and Karen Rutkowski, an expert in medical writing, share actionable insights on compliance.

  7. Global Compliance Made Easy
    5/6/2019

    Global clinical trial disclosure compliance is inherently complex, with over 39 registries, Most sponsors simply lack visibility into all the places they need to disclose information or what their commitments are. Automation can help make global compliance easier.

  8. Plain-Language Summaries Best Practices
    4/16/2019

    Today’s healthcare industry is hyper-focused on patient engagement. With plain-language summaries (PLS), clinical trial sponsors can make patient engagement more than a mantra. In this video, learn PLS best practices from two expert authorities.

  9. Interventional vs. Observational Studies
    4/15/2019

    Dr. Annette Stemhagen, SVP & Chief Scientific Officer, speaks to the differences between Interventional and Observational Studies.

  10. Overcoming Clinical Supply Chain Challenges In Investigator Initiated Studies
    4/12/2019

    Investigator Initiated Studies (IIS) offer pharmaceutical sponsor companies the benefit of increasing product knowledge and expanding the medical use of their drug. However, managing these studies presents unique clinical supply chain challenges and can become a very complex process. In this webinar, Almac’s clinical supply experts address these challenges and provide insight into how to best manage investigator initiated clinical studies.